Loading
A phase 2/3 trial testing HR070803 in colorectal cancer, active and no longer recruiting.
A Phase II/III Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer is a phase 2/3 interventional study registered as NCT05945901, led by Jiangsu HengRui Medicine, and active but no longer recruiting on the registry. Official title: A Phase II/III, Double-blind, Randomised, Multi-centre Study of HR070803 in Combination With Oxaliplatin, 5-fluorouracil, Calcium Folinate and Bevacizumab Versus FOLFOX in Combination With Bevacizumab for First-line Treatment of Advanced Colorectal Cancer. Planned enrolment is 669 participants (actual). The study started in 2023-08-14 and primary completion is expected in 2025-12-01. No results have been posted on ClinicalTrials.gov.
The full inclusion and exclusion criteria are on the registry record. Read 2026-10-07. Recruiting overall does not mean a particular site is open; ask the study team.
ClinicalTrials.gov data courtesy of the US National Library of Medicine.
Shares HR070803, Colorectal cancer.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/